Current information on the investigation of cases of narcolepsy after vaccination with Pandemrix
Thursday, August 26, 2010
In total, there are 12 cases of narcolepsy reported to the MPA from healthcare professionals in Sweden with a suspected relationship to vaccination with Pandemrix. In addition to the cases reported in Sweden and Finland there are a few further cases reported in France, Germany and Norway. An investigation is ongoing, but any relationship between the vaccination and the reported symptoms can not be concluded.
The MPA has earlier informed about reports of narcolepsy with a suspected relationship to vaccination with Pandemrix. In total, there are 12 cases of narcolepsy reported to the MPA from healthcare professionals in Sweden and 12 consumer reports describing similar symptoms but where further investigation is needed.
The MPA has through the EU network contacted the Member States and asked for information about similar reports. Up till now 18 countries have responded. In addition to the cases reported in Sweden and Finland there are a few further cases reported in France, Germany and Norway.
An investigation is ongoing. Several factors must be considered when evaluating the possibility of a relationship between the vaccination and the cases of narcolepsy. It is known that infectious diseases can give rise to neurological sequelae. The cases must be carefully evaluated and the diagnosis must be confirmed. The number of cases must be related to the number of individuals who earlier years have been diagnosed with narcolepsy, i.e. the number of narcolepsy that normally could be expected in the population.
A dialogue is ongoing between the Swedish health authorities; the MPA, the National Board of Health and Welfare and the Swedish Institute for Infectious Disease Control.
Within short, a meeting will be held with national clinical experts and experts in epidemiology. The meeting will discuss the situation and plan for follow up studies that can be needed to elucidate a possible relationship between vaccination and narcolepsy. Furthermore, information will be collected from relevant clinical departments in order to identify possible further cases nationwide.
This investigation is prioritized, in Sweden as well as in the EU. The MPA will update with further information as knowledge increases.
Please note the news item’s date of publishing. The Medical Products Agency does not update news.